Predict your next investment

SOFTWARE (NON-INTERNET/MOBILE) | Compliance
tnwinc.com

See what CB Insights has to offer

Founded Year

1982

Stage

Acquired | Acquired

About The Network

The Network builds solutions that prevent, detect and remediate misconduct to help companies maintain ethical cultures. The company provides the industry's first Integrated GRC Suite, as well as whistleblower hotlines, Code of Conduct services and full library of ethics and compliance training courses help more than 4,000 customers and half of the Fortune 500 identify and mitigate risks every day.

The Network Headquarter Location

333 Research Court Ste 100

Norcross, Georgia, 30092,

United States

800-253-0453

Latest The Network News

08:00 ET Wake Network, Inc. Receives Certificate of Drug Registration for Microdose Formulation in Jamaica

Sep 23, 2021

News provided by Share this article Share this article TORONTO, Sept. 23, 2021 /CNW/ - Wake Network, Inc. ("Wake" or the "Company"), a global leader in naturally-derived psilocybin production and the developer of genomics-based integration therapies, is pleased to announce the Company has received a Certificate of Drug Registration from the Jamaican Ministry of Health & Wellness for its naturally derived psilocybin microdose formulation, PSIL428. This is a critical milestone for Wake to run its own clinical trials by creating safety and efficacy data for its legal, proprietary psilocybin drug product, PSIL428. PSIL428 is one of the first psilocybin microdose formulations produced worldwide, which is derived from natural fungi material. This will allow the Company to address the growing demand for mushroom-based psilocybin microdosing used for therapeutic purposes. It also adds a layer of control that is committed to quality, consistency, and reliability from dose to dose. PSIL428 and the data on its safety and efficacy created through Wake's clinical trials will be available to clinics, treatment centres, and academic centres worldwide. As one of the only legal natural psilocybin drug forms in the world, it can be imported by  request for patient use in any country with  a special access program in place. "We are very excited about our natural psilocybin microdose formulation being registered as a research drug by the Jamaican Ministry of Health & Wellness", said Olga Chernoloz, Chief Scientific Officer of Wake, "It means that Wake and the clinical communities that are interested in investigating the clinical potential of psilocybin will now have access to this product. PSIL428's natural origin is an added bonus for those considering the potential benefits of full-spectrum formulations." PSIL 428 will be used in Wake's double-blind, randomized, placebo-controlled clinical trial assessing the effects of microdosing on anxiety and depression. The study is fully approved and registered with the National Institutes of Health, ClinicalTrials.gov Identifier:  NCT04989972 ABOUT WAKE NETWORK, INC. Wake Network, Inc. is a fungi bioscience company focused on advancing, through research, the field of psychedelic and fungi-based therapeutics. To address the growing need for psychedelic-assisted mental health support in medicine and society at large, Wake has partnered with academics, governments and best-in-class mycologists around the world. Wake is currently developing fungus-derived psilocybin and is making advancements in the engineering of novel psychedelic biologics, while working on proving out their safety through proprietary genetics-based integration therapies. Caution Regarding Forward-Looking Information This news release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations, or beliefs of future performance, are "forward-looking statements." Forward-looking statements can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. Forward looking statements are based on certain assumptions regarding the Company, including but not limited to expected growth, results of operations, performance, industry trends and growth opportunities. While the Company considers these assumptions to be reasonable based on currently available information, they may prove to be incorrect. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to: dependence on obtaining and maintaining regulatory approvals, including federal, provincial, municipal, local or other licences, to operate and expand the Company's facilities;  the Company's limited operating history and lack of historical profits; reliance on management; the Company's requirements for additional financing and the effect of capital market conditions and other factors on the availability of capital; competition, including from more established or better financed competitors; the need to secure and maintain corporate alliances and partnerships, including with research and development institutions, customers and suppliers; the Company's ability to develop technology and make scientific discoveries related to the biosynthesis of psilocybin and psilocin; the anticipated potential of biosynthesis to produce psychedelic compounds with the desired attributes; the Company's ability to develop an additional revenue stream from its work in biosynthesis of psilocybin and psilocin;  the Company's ability to conduct the clinical trials that it intends to;  the ability of the Company to discover new and/or more effective options for patients to treat their conditions; the development and implementation of medical protocols and treatment standard operating procedures for the use of psychedelic therapies; the Company's ability to successfully withstand the economic and geopolitical impact of the COVID-19 pandemic; the medical benefits, safety, efficacy, dosing and social acceptance of psychedelics; and the cultivation and harvest of psilocybe mushrooms; and any other factors or developments that may hinder the market or the Company's growth. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company has no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law. Readers should not place undue reliance on the Company's forward-looking statements. SOURCE Wake Network, Inc. For further information: For more information about Wake please visit our website www.wake.net or contact: Nick Murray, CEO, Wake Network, Inc., E: [email protected] , Tel: +1-833-925-3638; Investor Relations, Wake Network, Inc., E: [email protected] , Tel: +1 416-842-9003 Related Links

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing The Network

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned The Network in 4 CB Insights research briefs, most recently on Aug 18, 2021.

Expert Collections containing The Network

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

The Network is included in 1 Expert Collection, including Regtech.

R

Regtech

1,342 items

Technology that addresses regulatory challenges and facilitates the delivery of compliance requirements in FIs. Regulatory technology helps FIs and regulators address challenges ranging from traditional compliance and risk management to data reporting and transmission.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.